Sildenafil in Infants and Children
AbstractPulmonary arterial hypertension (PAH) management has been transformed in recent times with the advent of cheap and effective diagnostic tools and therapy. Sildenafil, a phosphodiesterase-V inhibitor, has been at the centre of this treatment, and its success in treating PAH has led to its widespread uptake in adult and paediatric pulmonary hypertension (PH), as a first line treatment choice. This might apply to persistent pulmonary hypertension of the newborn (PPHN) or bronchopulmonary dysplasia, as well as to more complex diseases, such as idiopathic pulmonary hypertension. Although recent data regarding long-term mortality and the repeal of Food and Drug Administration (FDA) approval has complicated the issue, Sildenafil continues to be the major treatment option for paediatric PH for patients in a variety of contexts, and this does not seem likely to change in the foreseeable future. In this review, we provide a summary of pulmonary hypertension in infants and children and the use of Sildenafil for such diseases. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Simonca, L.; Tulloh, R. Sildenafil in Infants and Children. Children 2017, 4, 60.
Simonca L, Tulloh R. Sildenafil in Infants and Children. Children. 2017; 4(7):60.Chicago/Turabian Style
Simonca, Larisa; Tulloh, Robert. 2017. "Sildenafil in Infants and Children." Children 4, no. 7: 60.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.